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of the potential for longevity-associated variants to dis-
rupt regulatory regions involved in isoform choice. We 
then related the expression of full length and 5′ trun-
cated FOXO3 isoforms to rs13217795 genotype in 
peripheral blood and skeletal muscle from individuals 
of different rs13217795 genotypes. FOXO3 isoforms 
displayed considerable tissue specificity. We determined 
that rs13231195 and its tightly aligned proxy variant 
rs9400239 may lie in regulatory regions involved in 
isoform choice. The longevity allele at rs13217795 was 
associated with increased levels of full length FOXO3 
isoforms in peripheral blood and a decrease in truncated 
Abstract The rs2802292, rs2764264 and rs13217795 
variants of FOXO3 have been associated with extreme 
longevity in multiple human populations, but the mecha-
nisms underpinning this remain unclear. We aimed to 
characterise potential effects of longevity-associated 
variation on the expression and mRNA processing of the 
FOXO3 gene. We performed a comprehensive assess-
ment of FOXO3 isoform usage across a wide variety of 
human tissues and carried out a bioinformatic analysis 
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FOXO3 isoforms in skeletal muscle RNA. We suggest 
that the longevity effect of FOXO3 SNPs may in part 
derive from a shift in isoform usage in skeletal mus-
cle away from the production of 5′ truncated FOXO3 
isoforms lacking a complete forkhead DNA binding 
domain, which may have compromised functionality.
Keywords FOXO3 · Longevity · Human · 
Variation · Isoforms
Introduction
Human ageing is highly heterogeneous. Some peo-
ple reach old age with good maintained health and 
quality of life, whilst others succumb to age-related 
diseases whilst still relatively young. The molecular 
basis behind these differences is still unclear. Long 
life often goes hand-in-hand with avoidance of age-
related disease, in a phenomenon termed compres-
sion of morbidity [12]. This suggests that the fac-
tors that govern lifespan also govern ‘health span’. 
Although environment and lifestyle contribute the 
largest component to successful ageing, genetic influ-
ences are also apparent. All-cause mortality was seen 
to decrease by 19% and 14% for the children of long-
lived mothers and long-lived fathers respectively, 
compared to their cohabiting spouses [8]. Offspring 
of long-lived parents demonstrated lower incidence 
of cancer, diabetes, heart disease and stroke [8] and 
were also demonstrated to demonstrate lower rates of 
age-related cognitive decline [9]. The heritability of 
longevity is reported to be ~ 16% [19]. These observa-
tions suggest that some people are genetically predis-
posed to a long life.
Several genetic variants associated with longevity 
have been reported. A large meta-analyses of asso-
ciations with parental lifespan carried out in 1 mil-
lion participants reported associations with several 
loci including those containing the CDKN2B-AS1, 
ATXN2/BRAP, FURIN/FES, ZW10, PSORS1C3, 
ABO, ZC3HC1, IGF2R EBF1 and FOXO3 genes 
[30]. FOXO3 (Forkhead Box O3) is one of four 
FOXO human homologues of Daf16, the first gene 
to be associated with lifespan in the nematode C. 
elegans [20]. It is a multifunctional transcriptional 
regulator with roles in multiple processes such as 
apoptosis, insulin signalling, metabolism, immu-
nity and inflammation, proteostasis and autophagy, 
response to cellular stress and control of cellular dif-
ferentiation [26]. Associations between genetic vari-
ation within or near the FOXO3 gene and longevity 
were first reported in a population of male American 
individuals of Japanese ancestry, which provided 
evidence for an association between rs2802292, 
rs2764264 and rs13217795 and extreme longevity 
[31]. These findings have now been replicated in 
11 different studies in populations of diverse ances-
tries [26]. The strongest association reported is with 
variant rs2802292, located in intron 2 of the FOXO3 
gene, which confers an odds ratio for extreme lon-
gevity of 2.75 and is also linked with biological 
markers of successful ageing and lower incidence of 
age-related disease [31]. This variant has also been 
linked with preservation of telomere length in the 
peripheral blood of individuals carrying longevity 
alleles at these loci [4].
Genetic variation can affect gene expression or 
activity by many mechanisms. Coding variants can 
change the amino acid sequence of the peptides 
produced, but the vast majority of variation associ-
ated with longevity, like most other traits, maps to 
non-coding regions of the genome [14]. Non-coding 
regions such as the 5′ and 3′ untranslated regions 
(UTRs), along with introns and intergenic regions 
often contain regulatory elements such as enhanc-
ers or sites of posttranscriptional modification. The 
FOXO3 longevity-associated variants are primarily 
located in or near intron 2 and do not alter the cod-
ing sequences of the gene. The underlying mecha-
nism by which these variants lead to extreme longev-
ity remains to be elucidated, although a search for 
linked functional variants indicated 13 putative regu-
latory SNPs that significantly modified 18 transcrip-
tion factor/enhancer binding sites in or near FOXO3 
[7]. Intronic variation is also commonly associated 
with alterations in alternative isoform usage, by vir-
tue of disruption of splicing regulatory elements 
such as intron splicing enhancer or silencer elements 
[1]. ENSEMBL indicates that human FOXO3 gene 
encodes three protein-coding alternatively expressed 
isoforms with differences in upstream exon usage 
(ENST00000343882.10, ENST00000406360.2 and 
ENST00000540898.1), although these are poorly 
characterised and little studied.
Here, we aimed to (i) characterise an expression 
profile for alternatively-expressed FOXO3 isoforms in 
a panel of human tissues, (ii) to map the rs2802292, 
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rs2764264 and rs13217795 variants of FOXO3 (and 
their proxies) to potential splicing or expression 
regulatory elements that may control FOXO3 iso-
form expression and (iii) to relate the expression of 
variants located in potential isoform regulatory ele-
ments to FOXO3 genotype in human peripheral blood 
and skeletal muscle. We confirmed the presence of 
two classes of FOXO3 isoforms: long (FOXO3-FL) 
and short (FOXO3-TR), and determined that whilst 
FOXO3-FL isoforms are present in all most FOXO3-
expressing tissues, the profile of FOXO3-TR is more 
restricted. We determined that variant rs13217795 
lies in a region of the genome with characteristics of 
an alternative promoter for FOXO3 with potential to 
regulate FOXO3-TR, and that genotype at this vari-
ant is associated with increased FOXO3-FL expres-
sion in peripheral blood and with decreased FOXO3-
TR expression in human skeletal muscle. FOXO3-TR 
is predicted to encode a truncated FOXO3 protein, 
which lacks part of the forkhead domain and several 
important points of posttranslational modification. 
We propose that the longevity effect conferred by 
rs13217795 may arise from a change in the balance 
of FOXO3-FL and FOXO3-TR isoforms towards a 
decrease in the production of the FOXO3-TR, which 
is predicted to lack DNA binding and to have lower 
activity.
Methods
Design of qRT-PCR probes to long and short FOXO3 
isoforms
The sequences of FOXO3 transcripts corresponding 
to long and short FOXO3 isoforms were accessed 
from the ENSEMBL genome browser (https:// www. 
ensem bl. org), and assays specific to the two full 
length isoforms (FOXO3-FL; ENST00000343882.10 
and ENST00000406360.2) or the truncated FOXO3 
isoform (FOXO3-TR; ENST00000540898.1) were 
designed. The FOXO3-FL assay was targeted 
over the exon 2/exon 3 boundary shared by both 
full length isoforms and thus did not differentiate 
between them. The FOXO3-TR assay was targeted 
over the exon 1a/exon 3 boundary and was specific 
to ENST00000540898.1 (Fig.  1). Probes and prim-
ers were as follows: FOXO3-FL; forward primer — 
GGA TAA GGG CGA CAG CAA CA, a reverse primer 
—GAA TCG ACT ATG CAG TGA CAG GTT and probe 
— FAM-CCG GAT GGA GTT CTTC-MBG. FOXO3-
TR; forward primer — GCC CTG GAA CCT TTT GGC 
TTAA, reverse primer — CGA CTA TGC AGT GAC 
AGG TTGT and probe FAM–CTC GGA AAA CAA 
ACTCC-MGB. Assays were purchased from Thermo 
Fisher (Waltham, USA).
Validation of FOXO3 isoform-specific assays
The performance of FOXO3-FL and FOXO3-TR 
assays was assessed using standard curve analysis. 
Fig. 1  The structure of FOXO3 isoforms. The structure of the 
exon structure and potential regulatory regions of the FOXO3 
gene are given here. Exons are given by black or grey boxes, 
and introns by a black line. The position of the FOXO3-FL 
and FOXO3-TR assays that span the exon 2–3 and exon 1a-3 
splice junctions respectively are indicated. The potential pro-
moter is indicated by the red line and the presence of a layered 
histone modification peak indicated in blue, as observed using 
https:// www. genome. ucsc. edu/. The positions of the extreme 
longevity index SNPs rs2802292, rs2764264 and rs13217795 
are given by a black star, and the rs9400239 proxy variant of 
rs13217795 is given by a grey star are indicated
 GeroScience
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One hundred nanograms of skeletal muscle total RNA 
was reverse transcribed for each sample in a total vol-
ume of 20µl using the Evoscript cDNA synthesis kit 
(Roche, Burgess Hill, UK) according to the manufac-
turer’s instructions. cDNA then underwent seven 1:2 
serial dilutions to establish accuracy, sensitivity and 
linear range. Reactions contained 2.5 µl TaqMan Uni-
versal Mastermix II (Thermo Fisher, Waltham, USA) 
0.9µM each primer, 0.25µM probe (Thermo Fisher, 
Waltham, USA), 1.25µl  H2O and 1µl cDNA in a total 
volume of 5µl. Cycling conditions were 95 OC for 
10 min prior to cycling, then 95 OC for 15 s and 60 
OC for a minute for 40 cycles.
Characterisation of the expression profile of 
FOXO3-FL and FOXO3-TR in human tissues
Samples from different human tissues (skeletal mus-
cle, pancreas, lung, pons, ovary, oesophagus, adipose, 
bladder, thyroid, breast, testes, adrenal gland, small 
intestine, thymus, trachea, cervix, prostate, medulla 
oblongata, colon, stomach, postcentral gyrus, kidney, 
hippocampus, spleen, salivary gland, parietal lobe, 
liver, cerebellum, heart, cerebral cortex, placenta, 
temporal lobe, uterus, total brain, pituitary, bone mar-
row, pooled islets and blood) were obtained from 
commercially-sourced, tissue-specific RNA panels 
(Becton, Dickinson & Co., Franklin Lakes, NJ, USA: 
BioChain Institute, Newark, CA, USA: Ambion®, 
Austin, TX, USA). One hundred nanograms of total 
RNA was reverse transcribed for each sample in a 
total volume of 20µl using the Evoscript cDNA syn-
thesis kit (Roche, Burgess Hill, UK) according to the 
manufacturer’s instructions. PCR reactions contained 
2.5µl TaqMan Universal Mastermix (no AMPerase) 
(Applied Biosystems, Foster City, USA), 0.9µM 
each primer, 0.25µM probe, 1.25µl  H2O and 1µl 
cDNA reverse transcribed as above in a total volume 
of 5µl. PCR conditions were a single cycle of 95ºC 
for 10 min followed by 40 cycles of 95  °C for 15  s 
and 60 °C for 1 min. The amount of FOXO3-FL and 
FOXO3-TR isoforms in each tissue sample was then 
quantified by isoform-specific qRT-PCR by the Com-
parative Ct method relative to the geometric mean of 
Beta 2 Microglobulin (B2M), Glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) and beta glucoroni-
dase (GUSB) endogenous control gene expression, 
with adjustment for assay efficiencies. Expression 
levels were then normalised to the average level of 
FOXO3-FL isoforms over the entire tissue panel.
Bioinformatic analysis of potential FOXO3 
regulatory regions
To determine for rs2802292, rs2764264 and 
rs13217795 to interfere with splicing or expression 
of the FOXO3 gene, we firstly determined all the 
proxy SNPS that were in complete linkage disequilib-
rium (D’ =  > 0.95, r2 > 0.80) with these index SNPs 
using SNPsnap (https:// data. broad insti tute. org/ mpg/ 
snpsn ap/ about. html). Index SNPs and proxies were 
then mapped to the known regulatory regions of the 
FOXO3 gene with reference to the UCSC genome 
browser (https:// www. genome. ucsc. edu/). SNPs were 
designated for follow-up if they were located within 
a predicted promoter element or within 50  bp of a 
splice site.
Profiling of FOXO3 isoforms in peripheral blood 
samples
We next profiled FOXO3 isoform levels in RNA 
extracted from 51 previously genotyped periph-
eral blood samples from the Exeter 10,000/Penin-
sula Research Bank study (https:// exete rcrfn ihr. org/ 
about/ exeter- 10000- prb/) selected on the basis of 
rs13217795 genotype. This collection is a cross sec-
tional population study consisting of samples col-
lected from volunteer individuals living in the South 
West of England and recruited since 2010. Whole 
blood samples were collected in 2011/2012 using the 
PAXgene system [5] and extracted using the PAX-
gene Blood RNA kit (Qiagen, Paisley, UK). Access 
to these anonymised samples was approved by the 
ethically approved Peninsula Research Bank Steer-
ing Committee (14/SW/1089). Our sample set con-
sisted of 18 individuals homozygous for the major 
allele of rs13217795 (TT), 17 samples heterozygous 
for rs13217795 (CT) and 17 samples homozygous 
for the longevity allele of rs13217795 (CC). Partici-
pant characteristics are given in Table  1. Levels of 
FOXO3-FL and FOXO3-TR isoforms were then quan-
tified relative to the geometric mean of the B2M and 
GAPDH genes by qRT-PCR as described above, with 
adjustment for assay efficiencies. Data were then nor-
malised to the mean level of the full-length isoforms 
in the rs13217795 heterozygous samples. Statistical 
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significance was then determined by ANOVA com-
paring age, sex and body mass index (BMI) covari-
ates by genotype. Significant covariates were taken 
into account within a univariate linear model using 
the IBM SPSS Statistics 26 program (IBM SPSS ver-
sion 26 release 26.0.0.0, Armonk, NY).
Characterisation of the expression profile of 
FOXO3-FL and FOXO3-TR in human skeletal 
muscle
In total, 64 human skeletal muscle samples were 
obtained from previously published studies of 
human muscle metabolism [6, 18, 21, 29]. Four 
samples were omitted due to unsuccessful geno-
typing. All volunteers abstained from alcohol and 
strenuous exercise for at least 48 h prior to the sam-
ple obtained. Samples were obtained from the vastus 
lateralis muscle and were dissected free of visible 
connective tissue, fat and blood immediately prior 
to snap freezing. Patient characteristics are given in 
Table  1. RNA was extracted from 20  mg homoge-
nised muscle sample using TRIzol reagent (Thermo 
Fisher, Waltham, USA). RNA concentration was 
quantified by ND-2000 Nanodrop Spectrophotom-
eter (NanoDrop,Thermo Fisher, Waltham City, 
USA). The genotype of each sample was determined 
by qPCR from the presence of heterogeneous RNA 
(hnRNA) in the RNA samples using 2.5 µl TaqMan 
Universal Mastermix II (Thermo Fisher, Waltham 
City, USA), 0.9µM of each primer and 0.2µM of 
each probe (genotyping assay ID = C_9174543_10) 
and 1  µl RNA in a total volume of 5  µl. Cycling 
conditions were 60 °C for 30 s, followed by 95 °C 
for 10  min prior to cycling. Samples were then 
cycled between 95 °C for 15 s and 60 °C for a min-
ute for 40 cycles. Following this, samples were 
held at 60 °C for 30 s. FOXO3 isoform levels were 
quantified by qRT-PCR as described above. Levels 
of FOXO3-FL and FOXO3-TR isoforms were then 
quantified relative to the geometric mean of the 
B2M and GAPDH genes by qRT-PCR as described 
above, with adjustment for assay efficiencies. GUSB 
was omitted from this analysis as it proved unstable 
baseline in our sample set. Data were then normal-
ised to the mean level of the full length isoforms in 
the rs13217795 heterozygous samples. Statistical 
significance was then determined by ANOVA com-
paring age, sex and body mass index (BMI) covari-
ates by genotype. Significant covariates were taken 
into account within a univariate linear model using 
the IBM SPSS Statistics 26 program (IBM SPSS 
version 26 release 26.0.0.0, Armonk, NY).
Assessment of FOXO3-FL isoform expression by age 
in human peripheral blood
To determine whether FOXO3 isoform expression 
alters with age, we carried out an assessment of 
the association between age and FOXO3-FL iso-
form expression exclusively in the 16 individuals 
Table 1  Table of 
participant details. Patient 
metrics for peripheral 
blood and skeletal muscle 
samples, displaying the 
average age, sex and BMI 
with SD and number of 
samples for each genotype. 
P values indicate one-way 












(CC) (n = 17)
p value
Mean age 49.94 (15.85) 53.75 (9.35) 51.24 (15.758) 0.738
Sex (% female) 81 44 65 0.090











(CC) (n = 8)
p value
Mean age 22.37 (3.47) 20.96 (3.09) 23 (4.34) 0.212
Sex (% female) 30 16 12.5 0.404
Mean BMI 23.06 (3.48) 24.56 (3.94) 25.45 (2.52) 0.160
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homozygous for the major (T/T) allele, to negate 
the effect of genotype by linear regression analysis. 
We were unfortunately unable to assess the effect of 
age on the truncated FOXO3-TR isoform since this 
isoform was only expressed in skeletal muscle, and 
the age range of the donors of our muscle samples 
was very limited (18 to 31 years).
Results
Validation of FOXO3-FL and FOXO3-TR assays
Quantitative real-time PCR assays were designed 
to FOXO3 full length (FOXO3-FL) and truncated 
(FOXO3-TR) isoforms and validated by standard 
curve analysis to determine accuracy, efficiency 
and linear range. FOXO3-FL and FOXO3-TR assays 
proved sensitive and accurate over a dynamic linear 
range of serial dilutions, with gradients of − 3.774 
and − 3.271 and R2 values between replicates of 
0.954 and 0.933 respectively. Representative standard 
curves for FOXO3-FL and FOXO3-TR isoforms are 
given in supplementary figure S1.
Expression pattern of FOXO3-FL and FOXO3-TR 
isoforms
The expression of FOXO3-FL and FOXO3-TR were 
determined over 38 commercially sourced different 
human tissues (Becton, Dickinson & Co., Frank-
lin Lakes, NJ, USA: BioChain Institute, Newark, 
CA, USA: Ambion®, Austin, TX, USA). All tissues 
except blood were found to express both FOXO3-TR 
and FOXO3-FL; however, FOXO3-TR was expressed 
at a reduced level in all tissues compared to FOXO3-
FL. The expression of FOXO3-FL compared to 
FOXO3-TR was highly variable by tissue type, 
with skeletal muscle expressing the highest level of 
FOXO3-TR to FOXO3-FL across the panel. FOXO3-
FL isoforms were highly expressed in most brain 
regions (postcentral gyrus, hippocampus, parietal 
lobe, cerebellum, cerebral cortex and temporal lobe) 
as well as in salivary and pituitary glands and whole 
blood. Levels of FOXO3-TR were highest in skeletal 
muscle, followed by many tissues of the endocrine, 
digestive or respiratory systems (pancreas, ovary, 
oesophagus, adrenal gland, adipose, testes, small 
intestine, thymus, trachea and lung) (Fig. 2).
Bioinformatic evaluation of FOXO3 SNPs for 
potential regulatory effects
We next assessed the potential for FOXO3 rs2802292, 
rs2764264 and rs13217795 SNPs and their tightly 
linked proxies to disrupt predicted regulatory regions. 
Variant rs2802292 had seven proxies in almost com-
plete linkage disequilibrium (LD) (D’ of 0.99 and 
r2 from 0.89 to 0.99; Table  2). None of these vari-
ants, or rs2802292 itself, was located within 50 bp of 
a splice site or within a predicted promoter sequence 
(Table  2). We identified no proxies in complete LD 
with rs2764264 and rs2764264 did not map close to 
any splice site or predicted regulatory region (Table 2). 
Conversely, rs13217795 demonstrated seven proxy 
SNPs in tight LD (D’ = 0.96 to 0.99; r2 = 0.84–0.95). 
Of these, although none mapped in proximity to a 
splice site, rs9400239 mapped to the alternative non-
coding exon 1a of FOXO3-TR, and rs13217795 itself 
mapped to a predicted regulatory region for an alter-
native promoter with potential to regulate the expres-
sion of FOXO3-TR (Table 2; Fig. 1). As rs9400239 and 
rs13217795 are in almost complete LD, we elected to 
take forward rs13217795 for analysis on the basis that it 
will capture both SNPs.
The longevity-associated C allele of rs13217795 is 
associated with elevated expression of FOXO3-FL 
isoforms in peripheral blood
We measured levels of FOXO3-FL and FOXO3-TR 
isoforms in RNA from human peripheral blood from 
the Exeter 10 K study, and related these to genotype 
at rs13217795. We identified that increased expres-
sion of the FOXO3-FL isoforms was associated with 
the extreme longevity ‘C’ allele, and that effects were 
apparent in both heterozygotes and longevity allele 
homozygotes, with effects demonstrating a dominant 
pattern, with no difference between individuals car-
rying either one or two C alleles (Fig. 3). In heterozy-
gous individuals (‘C/T’), the logged mean expression 
of FOXO3-FL isoforms was 1.05 (SD = 0.33) com-
pared with − 0.73 (SD = 0.19) in individuals homozy-
gous for the ‘T’ allele (p = 0.004). In individuals car-
rying two copies of the longevity ‘C’ allele, logged 
mean expression was 1.1 (SD = 0.40) compared 
with 0.73 (SD = 0.249) in individuals homozygous 
for the major ‘T’ allele (p = 0.003). We detected no 
expression of FOXO3-TR isoforms in peripheral 
GeroScience 
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blood, consistent with our findings in the tissue panel 
(Fig. 2).
The longevity-associated C allele of rs13217795 is 
associated with decreased expression of FOXO3-TR 
isoforms in skeletal muscle
We measured levels of FOXO3-FL and FOXO3-TR 
isoforms in RNA from human skeletal muscle sam-
ples, and related these to genotype at rs13217795. 
In contrast to our findings in in peripheral blood, we 
detected no association of FOXO3-FL isoforms with 
genotype at rs13217795 in skeletal muscle (Fig.  4). 
FOXO3-TR isoforms were expressed in muscle, con-
sistent with our findings in the tissue panel (Fig. 2). 
Furthermore, we determined that in the skeletal mus-
cle of individuals carrying two copies of the lon-
gevity ‘C’ allele, the logged mean expression of the 
FOXO3-TR isoform was 0.07 (SD = 0.07) compared 
with 0.12 (SD = 0.06) in individuals heterozygous 
for rs13217795 (p = 0.013). Levels of FOXO3-TR 
isoforms also demonstrated a trend towards reduced 
expression in C/C individuals compared with individ-
uals homozygous for the ‘T’ allele, although this was 
not statistically significant, probably due to the large 
spread of data in the ‘T/T’ individuals. Comparison 
of FOXO3-TR levels in individuals heterozygous for 
the C allele did not display a similar reduction rela-
tive to TT homozygotes; however, levels are if any-
thing slightly elevated in heterozygotes. This may 
Fig. 2  The expression of FOXO3 isoforms across multiple 
tissues. The figure gives the expression pattern of full length 
and truncated FOXO3 isoforms across an extended panel of 
human tissues. Mean relative mRNA expression in arbitrary 
units (AU) is given on the Y axis, whilst tissue identity is given 
on the X axis. Full length isoforms ENST00000343882.10 and 
ENTS0000406360.2 (FOXO3-FL) are given by light grey bars 
and the truncated isoform ENST00000540898.1 (FOXO3-TR) 




suggest that 2 copies of the C allele may be necessary 
to observe a reduction in level.
The full length FOXO3-FL isoforms display an 
association with age in human peripheral blood
To determine whether the FOXO3-FL isoforms dis-
played any evidence of differential expression with 
age, we correlated FOXO3-FL expression in periph-
eral blood mRNA with participant age in individuals 
homozygous for the major (T/T) allele of rs13217795 
by linear regression. We identified that as expected, 
FOXO3-FL isoform expression declined with age 
(beta coefficient =  − 0.64; SE = 0.003, p = 0.012; sup-
plementary figure S2).
Discussion
The FOXO3 gene is one of 4 human homologues of 
the C. elegans Daf-16 gene, which was amongst the 
first genes associated with lifespan in animal models 
[20]. FOXO3 belongs to a gene family which encodes 
4 transcription factors (FOXO1, FOXO3, FOXO4 and 
FOXO6) which are conserved from nematodes to 
mammals [24]. The unique characteristics of FOXO’s 
place them perfectly to act as cellular sensors, to 
allow cells to adapt and respond to their internal and 
external environment. Accordingly, FOXO proteins 
have important roles in multiple fundamental pro-
cesses in cells, such as in control of metabolism, cell 
division and differentiation status and response to 
cellular stress [17] and unsurprisingly, have particu-
lar importance in regulation of ageing and longevity 
[25]. Genetic variation in the FOXO3 gene has been 
linked with extreme longevity in multiple human 
populations [26, 31], although the molecular basis for 
this remains to be elucidated. Here, we have charac-
terised the expression profile alternatively expressed 
isoforms of the FOXO3 gene across a panel of human 
tissues, mapped SNPs associated with extreme lon-
gevity in human populations to the regulatory regions 
of the FOXO3 gene and identified that individuals 
carrying extreme longevity alleles at rs13217795 
demonstrate elevated expression of full length 
FOXO3 isoforms in peripheral blood and decreased 
expression of the truncated FOXO3 isoform in skel-
etal muscle.
FOXO proteins share a Forkhead DNA binding 
domain, which is approximately 100  bp long, and 
consists of three alpha helices and three beta pleated 
sheets flanked by looped and winged sections [13]. 
Table 2  Potential 
regulatory effects of 
longevity-associated 
variants at FOXO3 and 
their proxies. We identified 
proxies for the three 
longevity-associated 
FOXO3 variants and 
mapped these to potential 
regulatory regions in or 
around the FOXO3 gene as 
described in (https:// www. 
genome. ucsc. edu/, accessed 
20.01.21). Index SNPS are 
indicated in bold type, and 
those mapping to potential 
regulatory regions in 
italicised underlined type. 
Linkage disequilibrium is 
given by measured of D’ 
and r2





rs2802292 - - Intron 2 No No
rs2253310 0.99 0.99 Intron 2 No No
rs2764261 0.99 0.88 Intron 2 No No
rs2802295 0.99 0.98 Intron 2 No No
rs2764265 0.99 0.89 Intron 2 No No
rs2490272 0.99 0.94 Intron 2 No No
rs2802288 0.99 0.99 Intron 2 No No
rs2802290 0.99 0.99 Intron 2 No No
rs2764264 - - Intron 2 No No
rs13217795 - - Intron 2 No Yes
rs71015554 0.99 0.84 Intron 2 No No
rs9398171 0.97 0.93 Intron 2 No No
rs9400239 0.99 0.95 Exon 1a No No
rs4946932 0.99 0.95 Intron 2 No No
rs10457180 0.99 0.86 Intron 2 No No
rs2022464 0.99 0.94 Intron 2 No No
rs138068040 0.96 0.91 Intron 2 No No
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FOXO proteins bind as monomers to their down-
stream targets, and have been reported to be capa-
ble of both transactivation through direct binding to 
targets [10], or to gene repression, through DNA-
independent indirect mechanisms [3, 11]. Transac-
tivation or inhibitory activity can also be moderated 
by binding with cofactors such as SIRT1, CBP and 
p300 [27]. FOXOs are themselves regulated by post-
translational modifications such as phosphorylation, 
acetylation, methylation and ubiquitination [32]. The 
FOXO3-FL and FOXO3-TR isoforms demonstrate 
marked differences in their structure (Fig.  5). The 
full length isoforms contain the full length forkhead 
domain, whereas the truncated isoform contains only 
part of the S2 spacer, the S3 spacer and the 5th Helix 
H5, but is missing Helices H1 to H4 and spacer S1. 
The lack of a complete forkhead domain makes it 
unlikely that the truncated isoform would be able to 
efficiently bind DNA and regulate its downstream tar-
gets. The truncated FOXO3 isoform is also lacking 
some points of posttranslational modification includ-
ing phosphorylation sites at T32 and T179, and S207. 
T32 is one of three FOXO3 sites modified by AKT 
and SGK, that has been shown to create binding sites 
for the chaperone protein 14–3-3, which binds FOXO 
Fig. 3  Relationship between FOXO3 genotype and FOXO3 
isoform expression in peripheral blood RNA samples. The 
relationship between FOXO3 full length and truncated iso-
form levels and genotype at rs13217795 is given for periph-
eral blood samples originating from the Exeter 10  K study. 
Isoform identity and genotype are given on the X axis, and 
median relative expression in arbitrary units (AU) is given on 
the Y axis. Statistical significance of logged data is indicated 
by stars; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. Circles indicate 
major allele (T) homozygotes, squares indicate heterozygous 
samples (C/T) and triangles indicate minor allele (C) homozy-
gotes. Error bars represent interquartile range. No expression 
of FOXO3-TR isoform was detected in peripheral blood
Fig. 4  Relationship between FOXO3 genotype and FOXO3 
isoform expression in skeletal muscle RNA samples. The rela-
tionship between FOXO3 full length and truncated isoform 
levels and genotype at rs13217795 is given for muscle samples 
originating from the SPADE, BIER, TIME and INDIA stud-
ies. Isoform identity and genotype are given on the X axis, and 
median relative expression in arbitrary units (AU) is given on 
the Y axis. Statistical significance of logged data is indicated 
by stars; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. Circles indicate 
major allele (T) homozygotes, squares indicate heterozygous 
samples (C/T) and triangles indicate minor allele (C) homozy-
gotes. Error bars represent interquartile range
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proteins in the nucleus and allows their active export 
[2]. This may mean that the truncated isoform also 
has altered ability to translocate between nucleus and 
cytoplasm, which has been shown to be a key factor 
in stress responses and determination of lifespan in 
nematodes [22, 28].
There may also be differences in miRNA regula-
tion between isoforms, since the 3′ UTR of FOXO3-
TR is truncated. The FOXO3-FL isoforms contain 
additional binding sites for isoforms contain addi-
tional binding sites for hsa-miR-29-3p, hsa-miR-
155-5p, hsa-miR-9-5p, hsa-miR-27-3p, hsa-miR-
122-5p, hsa-miR-142-3p.2 and hsa-miR-217, which 
are not present in FOXO3-TR. Although not all of 
these predicted binding sites have been functionally 
validated, inhibition of hsa-miR-155-5p has been 
shown to rejuvenate aged mesenchymal stem cells 
and enhances cardioprotection following infarction 
[16]. The FOXO3-TR isoform may therefore com-
pete with the full-length transcripts for miRNAs that 
modulate (downregulate) FOXO3 expression and, 
hence, the amount of protein. The longevity (minor) 
allele of rs13217795 and/or its proxies may function-
ally increase the amount of protein by serving as a 
miRNA sponge. There are also interactions with circ-
FOXO3, a circular RNA, which we have previously 
described to be associated with cellular senescence 
and parental longevity in humans [15]. CircFOXO3 
has a role in cellular proliferation via sponging of 
miR-9-5p [23].
Our study is the first to characterise the alterna-
tively expressed FOXO3 isoforms in humans, and 
the first to report a shift in FOXO3 isoform usage in 
human samples from different tissues in response to 
genotype at loci associated with extreme longevity. 
The tissue-specific effects we have noted also raise 
the possibility that different tissues may have differ-
ent responses to genotype at such loci, particularly 
where the truncated isoform is predominant. Our 
work also has caveats; we have demonstrated these 
effects only at the level of the mRNA transcript, but 
others have documented the presence of a similar 5′ 
truncated FOXO3 protein isoform by Western blot in 
mouse [33]. We are also unable to precisely pinpoint 
the causal variant in or near FOXO3 that underpins 
the effect we note, because of the tight LD between 
variants, but the most likely candidate is rs13217795 
since it lies in a region of the FOXO3 gene with char-
acteristics of an alternative promoter. We cannot 
rule out an effect of its tightly linked proxy variant 
rs9400239, which lies in the alternatively expressed 
exon 1a of the FOXO3 gene. Exon 1a is a non-cod-
ing exon, so will not alter the coding sequence of the 
truncated isoform, but it is possible that it confers 
some alteration in regulatory potential. Previous work 
has suggested that some of the longevity–associated 
SNPs at the FOXO3 locus may act as a cis-regulatory 
unit that influences the expression level of neigh-
bouring genes [7]. It is possible therefore that the 
longevity effect is due to both the potential alteration 
in overall FOXO3 activity brought by the change in 
expression of FOXO3 isoforms, but also the changes 
in the expression of other genes that are influenced by 
FOXO3.
We propose here a potential explanation for the 
association reported in multiple human popula-
tions between genetic variation in intron 2 of the 
FOXO3 gene and extreme longevity. We suggest 
Fig. 5  The functional domains of the FOXO3 protein in 
relation to isoform structure. The structure of the forkhead 
domain and position of functional posttranslational modifica-
tions within the FOXO3 gene relative to its isoform structure 
is given. The position of the forkhead domain is indicated by 
the red arrow. The five helices are given by blue boxes, and the 
spacer regions by orange boxes. The exon structure is given by 
black and grey boxes. Points of posttranslational modification 
at T32 and T179, and S207 are given by blue stars
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that rs13217795, or one of its tightly-linked proxies, 
is capable of bringing about an upregulation of full-
length FOXO3 isoforms in some tissues, with down-
regulation of truncated forms of FOXO3 being associ-
ated with inheritance of two copies of the longevity 
allele in others, most notably skeletal muscle. Some 
tissues may exhibit both phenomena, since we have 
observed differences between tissues in response. 
The truncated isoform of FOXO3 is likely to have 
compromised DNA binding potential due to its inter-
rupted forkhead domain, and may also have altered 
subcellular trafficking because of disrupted posttrans-
lational modification. We propose that in individuals 
carrying one or more alleles of the rs13217795 vari-
ant (or a tightly linked proxy SNP), the shift towards 
full-length FOXO3 isoforms and away from truncated 
transcripts brings about an enhancement of FOXO3 
activity, with consequent effects on cellular processes 
involved in determination of lifespan.
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